Vanguard Group
MAZE

Vanguard Group’s Maze Therapeutics MAZE Stock Holding History

Vanguard Group’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$70.3M Buy
1,697,015
+362,060
+27% +$12.4M ﹤0.01% 2000
2025
Q3 		$34.6M Buy
1,334,955
+915,342
+218% +$15.5M ﹤0.01% 2338
2025
Q2 		$5.15M Sell
419,613
-246,941
-37% -$2.57M ﹤0.01% 3209
2025
Q1 		$7.34M Buy
+666,554
New +$8.02M ﹤0.01% 3017

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
GCGM
General Catalyst Group Management Cambridge, Massachusetts $184M AUM 50.45% 1-Year Est. Return

Vanguard Group's MAZE Position: Q4 2025 in Review

Vanguard Group increased its Maze Therapeutics (MAZE) stake by 27% in Q4 2025, buying an estimated $12.4M and bringing the position to 1,697,015 shares worth $70.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2000.

Vanguard Group first reported a position in MAZE in Q1 2025 and has held it in 4 quarters since. 143 funds tracked by Wall St. Rank hold MAZE as of Q4 2025.

  • Vanguard Group held 1,697,015 shares of Maze Therapeutics worth $70.3M as of Q4 2025.
  • Vanguard Group bought 362,060 Maze Therapeutics shares in Q4 2025, an estimated $12.4M.
  • Maze Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2000 holding.
  • Vanguard Group first reported a position in Maze Therapeutics in Q1 2025 and has held it in 4 quarters since.
  • 143 funds tracked by Wall St. Rank held Maze Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.